|

Immune Profiling for Cancer Immunotherapy Response

RECRUITINGSponsored by Dartmouth-Hitchcock Medical Center
Actively Recruiting
SponsorDartmouth-Hitchcock Medical Center
Started2022-10-03
Est. completion2027-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06116032

Summary

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
* Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

Exclusion Criteria:

* Pregnant women/fetuses/neonates
* Prisoners
* Decision-impaired individuals

Conditions4

Blood CancerCancerHematologic MalignancyTumor, Solid

Locations1 site

Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Hannah G Stolrow, BA7205174950hannah.stolrow@dartmouth.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.